Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2011 Mar 16;2011(3):CD007294.
doi: 10.1002/14651858.CD007294.pub2.

Chemotherapy wafers for high grade glioma

Michael G Hart  1 , Robert Grant, Ruth Garside, Gabriel Rogers, Margaret Somerville, Ken Stein
Affiliations
Meta-Analysis

Chemotherapy wafers for high grade glioma

Michael G Hart et al. Cochrane Database Syst Rev. .

Abstract

Background: Standard treatment for high grade glioma (HGG) usually entails surgery (either biopsy or resection) followed by radiotherapy plus or minus temozolomide. Implanting wafers impregnated with chemotherapy agents into the resection cavity represents a novel means of delivering drugs directly to the resection cavity with potentially fewer systemic side effects. It is not clear how effective this modality is or whether it should be recommended as part of standard care for patients with HGG.

Objectives: To estimate the clinical effectiveness of chemotherapy wafers for patients with HGG.

Search strategy: The following databases were searched: CENTRAL (issue 4. 2010); MEDLINE and EMBASE. The original search strategy also included: Science Citation Index; Physician Data Query; and the meta-Register of Controlled Trials. Reference lists of all identified studies were searched. The Journal of Neuro-Oncology and Neuro-oncology were hand searched from 1999 to 2010, including all conference abstracts. Neuro-oncologists, trial authors and drug manufacturers were contacted regarding ongoing and unpublished trials.

Selection criteria: Patients included those of all ages with a histologically proven diagnosis of HGG (using intra-operative analysis when undergoing first resection). Therapy could be instigated for either newly diagnosed disease (primary therapy) or at recurrence. Interventions included insertion of chemotherapy wafers to the resection cavity. Included studies had to be randomised controlled trials (RCTs).

Data collection and analysis: Two independent review authors assessed the search results for relevance and undertook critical appraisal according to pre-specified guidelines.

Main results: In primary disease two RCTs assessing the effect of carmustine impregnated wafers (Gliadel®) and enrolling a total of 272 participants were identified. Survival was increased with Gliadel® compared to placebo (hazard ratio (HR) 0.65, 95% Confidence Interval (CI) 0.48 to 0.86, P = 0.003). In recurrent disease a single RCT was included comparing Gliadel® with placebo and enrolled 222 participants. It did not demonstrate a significant survival increase (HR 0.83, 95% CI 0.62 to 1.10, P = 0.2). There was no suitable data for any of the secondary outcome measures. Adverse events were not more common in either arm and are presented in a descriptive fashion.

Authors' conclusions: Carmustine impregnated wafers (Gliadel®) result in improved survival without an increased incidence of adverse events over placebo wafers when used for primary disease therapy. There is no evidence of benefit for any other outcome measures. In recurrent disease Gliadel® does not appear to confer any additional benefit.

PubMed Disclaimer

Conflict of interest statement

All authors report no conflict of interest.

Figures

1.1
1.1. Analysis
Comparison 1 Primary Gliadel Therapy, Outcome 1 Survival.
2.1
2.1. Analysis
Comparison 2 Gliadel for Recurrence, Outcome 1 Survival.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Brem 1997 {published data only}
    1. Brem H, Piantadosi S, Burger PC. Placebo‐controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrence. The Lancet 1995;345:1008‐12. - PubMed
Valtonen 1997 {published data only}
    1. Valtonen S, Timonen U, Toivanen P. Interstitial Chemotherapy with Carmustine‐loaded Polymers for High‐grade Gliomas: A Randomized Double‐blind Study. Neurosurgery 1997;41(1):44‐8. - PubMed
Westphal 2003 {published data only}
    1. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro‐oncology 2003;5(2):79‐88. - PMC - PubMed
Westphal 2006 {published data only}
    1. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long‐term follow‐up of a multicentre controlled trial. Acta Neurochirurgica 2006;148:269‐275. - PubMed

References to studies excluded from this review

Brem 1995 {published data only}
    1. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU‐loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. Journal of Neuro‐oncology 1995;26:111‐23. - PubMed
Brophy 2004 {published data only}
    1. Brophy J, Chen J. Use of carmustine implants (GLIADEL wafer) in patients with malignant glioma at The McGill University Health Centre. Technology Assessment Unity of the McGill University Health Centre 2004.
Dalbasti 2002 {published data only}
    1. Dalbasti T, Oktar N, Cagli S, Ozdamar N. Local interstitial chemotherapy with sustained release bucladesine in de novo glioblastoma multiforme: a preliminary study. Journal of Neuro‐Oncology 2002;56:167‐174. - PubMed
FDA 2003 {published data only}
    1. US Food, Drug Administration. Approval Package: Gliadel Wafer (20‐637/S16). http://www.fda.gov. [http://www.fda.gov.cder/foi/nda/2003/20‐637x016_Gliadel.htm]
Garside 2007 {published data only}
    1. Garside R. Pitt M. Anderson R. Rogers G. Dyer M. Mealing S, et al. The effectiveness and cost‐effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high‐grade glioma: a systematic review and economic evaluation.. Health Technology Assessment (Winchester, England) 2007;11(45):iii‐iv, ix‐221. - PubMed
Kleinberg 2004 {published data only}
    1. Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, et al. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Investigation 2004;22:1‐9. - PubMed
LaRocca 2006 {published data only}
    1. Rocca RV, Hodes J, Villanueva WG, Vitaz TW, Morassutti DJ, Doyle MJ, et al. A Phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high‐grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion. Neuro‐oncology 2007;8:391‐500.
Mulrow 2003 {published data only}
    1. Mulrow M. Long term efficacy of the Gliadel (R) wafer in patients with high‐grade malignant gliomas: A meta analysis. 12 European Congress of Neurosurgery. 2003:513‐516.
Perry 2007 {published data only}
    1. Perry J. Chambers A. Spithoff K. Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current Oncology 2007;14(5):189‐94. - PMC - PubMed
Sheleg 2002 {published data only}
    1. Sheleg SV, Korotkevich EA, Zhavrid EA. Local chemotherapy with cisplatin‐depot for glioblastoma multiforme. Journal of Neuro‐oncology 2004;60:53‐59. - PubMed

Additional references

Castillo 2004
    1. Castillo MS, FG Davis, Surawicz T, Bruner JM, Bigner S, Coons S, et al. Consistency of Primary Brain Tumor Diagnoses and Codes in Cancer Surveillance Systems. Neuroepidemiology 2004;23:85‐93. - PubMed
Counsell 1996
    1. Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989‐90. Journal of Neurology, Neurosurgery & Psychiatry 1996;61(2):143‐50. - PMC - PubMed
CRD 2009
    1. Centre for Reviews and Dissemintation. Systematic Reviews: CRD's guidance for undertaking reviews in health care. York: York Publishing Services Limited, 2009.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Devaux 1993
    1. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy and survival in malignant glial neoplasms. Journal of Neurosurgery 1993;78:767‐75. - PubMed
Fleming 2002
    1. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clinical Pharmacokinetics 2002;41(6):403‐19. - PubMed
Fowkes 1991
    1. Fowkes FGR, Fulton PM. Critical appraisal of published research: introductory guidelines. British Medical Journal 1991;302:1136‐40. - PMC - PubMed
Gallego 2007
    1. Gallego JM, Barcia JA, Barcia‐Marino C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir (Wien) 2007;149:261‐65. - PubMed
GMT Group 2002
    1. Glioma Meta‐Analysts Trialists (GMT) Group. Chemotherapy for High Grade Glioma. Cochrane Database of Systematic Reviews 2002, Issue Issue 3. Art. No.: CD003913. DOI: 10.1002/14651858. [DOI: 10.1002/14651858] - DOI - PMC - PubMed
Grant 2004
    1. Grant R. Overview: Brain Tumour Diagnosis and Management/Royal College of Physicians Guidelines. Journal of Neurology, Neurosurgery and Psychiatry 2004;75(Suppl II):ii18‐ii23. - PMC - PubMed
Hart 2000
    1. Hart MG, Grant R, Metcalfe SE. Biopsy versus resection for High Grade Glioma. Cochrane Database of Systematic Reviews 2000, Issue Issue 2. Art. No.: CD002034. DOI: 10.1002/14651858. [DOI: 10.1002/14651858] - DOI
Hensen 2008
    1. Hensen JW, Ulmer S, Harris GJ. Brain Tumour Imaging in Clinical Trials. American Journal of Neuroradiology 2008;29:419‐24. - PMC - PubMed
Higgins 2009
    1. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2.[updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org.
Hochberg 1980
    1. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907‐11. - PubMed
Juni 2001
    1. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6. - PMC - PubMed
Kaal 2004
    1. Kaal ECA, Vecht CJ. The management of brain edema in brain tumour. Current Opinion in Oncology 2004;16:593‐600. - PubMed
Karnofsky 1948
    1. Karnofsky DA. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634‐56.
Kim 2006
    1. Kim L, Glantz M. Chemotherapeutic option for primary brain tumours. Current treatment options in oncology 2006;7:467‐78. - PubMed
Kleihues 1993
    1. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathology 1993;3(3):255‐68. - PubMed
Kreth 1993
    1. Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. Journal of Neurosurgery 1993;78:762‐6. - PubMed
Mauer 2008
    1. Mauer ME, Bottomley A, Taphoorn MJB. Evaluating health‐related quality of life and symptom burden in brain tumour patients: instruments for use in clinical trials and clinical practice. Current Opinion in Neurology 2008;21:741‐53. - PubMed
MedDRA 2008
    1. Medical Dictionary for Regulatory Authorities. http://www.meddramsso.com/MSSOWeb/index.htm.
Nazarro 1990
    1. Nazzaro J, Neuwelt E. The role of surgery in the management of supratentorial intermediate and high‐grade astrocytomas in adults. Journal of Neurosurgery 1990;73:331‐4. - PubMed
NICE 2007
    1. National Collaborating Centre for Cancer. Improving Outcomes for People with Brain and Other CNS Tumours: The Evidence Review. http://www.nice.org.uk/guidance/index.jsp?action=download&o=28963.
Parmar 1998
    1. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature of endpoints. Statistics in Medicine 1998;17:2815‐34. - PubMed
Rampling 2005
    1. Rampling R, James A, Papanastassoiu V. The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. Journal of Neurology, Neurosurgery and Psychiatry 2005;75(Suppl II):ii24‐ii30. - PMC - PubMed
SHS 2009
    1. Scottish Health Statistics: Brain and central nervous system cancer, 2009. ISD Scotland; http://www.isdscotland.org/isd/1395.htm.
Siker 2006
    1. Siker ML, Chakravarti A, Mehta MP. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. Critical reviews in Oncology‐Haematology 2006;60(2):99‐111. - PubMed
Stewart 2002
    1. Stewart LA. Chemotherapy in adult high‐grade glioma: a systematic review and meta‐analysis of individual patient data from 12 randomised trials.. Lancet 2002;359:1011‐8. - PubMed
Stupp 2005
    1. Stupp R, Mason WP, Bent MJ. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups. National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.. New England Journal of Medicine 2005;352:987‐96. - PubMed
Walker 1978
    1. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. Journal of Neurosurgery 1978;49:333‐43. - PubMed
Weber 2005
    1. Weber EL, Goebel EA. Cerebral oedema associated with Gliadel wafers: Two case studies. Neuro‐oncology 2005;7:84‐89. - PMC - PubMed
Wen 2010
    1. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated Response Assessment Criteria in High Grade Gliomas: Response Assessment in Neuro‐Oncology Working Group. Journal of Clinical Oncology 2010;28(10):1963‐72. - PubMed
Whittle 2003
    1. Whittle IR, Lyles S, Walker M. Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel. Journal of Neurosurgery 2003;17:352‐4. - PubMed
WHO 1982
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982;5:649‐655. - PubMed
Winger 1989
    1. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low‐grade glioma. Journal of Neurosurgery 1989;71(4):487‐93. - PubMed

MeSH terms

Substances